Please enable Javascript
CRPC
Metastatic castration-resistant prostate cancer
Advertisement
Can PSMA PET Imaging Predict Lu-PSMA Outcomes?
Koichiro Kimura, MD, PhD
RLT
|
July 8, 2025
Dr. Kimura shares insights on PSMA PET/CT metrics and their potential role in guiding treatment decisions for mCRPC.
View More
Total Tumor SUVmean Robustly Predicts PSA PFS for Patients With mCRPC
Emily Menendez
RLT
|
June 25, 2025
Quantitative analysis outperformed visual analysis in the prediction of outcomes for patients undergoing Lu-PSMA therapy.
Read More
Monitoring [177Lu]Lu-PSMA Therapy in mCRPC: Clinical Protocols
Jessica Ganga
RLT
|
June 25, 2025
New research explores the prognostic potential of LuPSMA-SPECT/CT with RECIP 1.0 in patients with advanced prostate cancer.
Read More
EVOLUTION: Lu-PSMA With Ipi/Nivo in mCRPC
Scott Tagawa, MD, MS, FACP
RLT
|
June 5, 2025
Dr. Tagawa explains the rationale for EVOLUTION, a phase II analysis of Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC.
View More
TheraP: Clonal Hematopoiesis in mCRPC Patients Receiving Lu-PSMA or Cabazitaxel
Scott Tagawa, MD, MS, FACP
RLT
|
June 5, 2025
Dr. Tagawa contextualizes a post hoc analysis on clonal hematopoiesis in those who received 177Lu-PSMA-617 or cabazitaxel.
View More
ProstACT GLOBAL: TLX591 and Best SOC for Patients With PSMA-Expressing mCRPC
Scott Tagawa, MD, MS, FACP
RLT
|
June 5, 2025
Dr. Tagawa showcases the ProstACT Global trial, a phase III study of 177Lu-rosptamab in patients with mCRPC.
View More
VIOLET: Terbium-161 Radioligand Treatment in Patients With mCRPC
Scott Tagawa, MD, MS, FACP
RLT
|
June 5, 2025
Dr. Tagawa breaks down the VIOLET study, a single-arm phase I/II first-in-human results of terbium-161Tb-PSMA-I&T.
View More
Cabazitaxel vs Lutetium-177: Efficacy for Metastatic Castration-Resistant Prostate Cancer
Zeynep Irem Ozay, MD
RLT
|
June 4, 2025
Dr. Ozay discusses her study that compared the efficacy of cabazitaxel with lutetium Lu-177 in patients with mCRPC.
View More
ENZA-p: Predictive, Prognostic Value of Baseline PSMA Total Tumor Volume, SUV Mean
Louise Emmett, MD
RLT
|
May 31, 2025
Louise Emmett, MD, discusses the ENZA-p trial which studied enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617.
View More
Clonal Mutations More Common After 177Lu-PSMA-617 Than Cabazitaxel
Lauren Dembeck, PhD
CRPC
|
May 29, 2025
Researchers studied clonal hematopoiesis mutations in patients treated with 177Lu-PSMA-617 or cabazitaxel for prostate cancer
Read More
Higher Progression-Free Survival Provided by LuPSMA Plus Ipi/Nivo Over LuPSMA Alone in Patients With mCRPC
Emily Menendez
RLT
|
May 29, 2025
The addition of ipi/nivo to LuPSMA improved PSA-PFS over 12 months in patients with mCRPC.
Read More
18F-Flotufolastat-PET Aids in Detection of Hematologic Malignancy in Patients With mCRPC Treated With 177Lu
Emily Menendez
RLT
|
May 23, 2025
18F-flotufolastat-PET can help determine severe hematologic toxicity in patients with mCRPC who are treated with 177Lu.
Read More
ASCO Guideline Update Recommends Androgen-Deprivation Therapy, Somatic Genetic Testing for mCRPC
Emily Menendez
CRPC
|
May 6, 2025
Radium 223 is recommended for patients with symptomatic bone-only disease.
Read More
FDA Approves 177Lu Vipivotide Tetraxetan for PSMA+ mCRPC Treatment Before Chemotherapy
Emily Menendez
CRPC
|
March 31, 2025
177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.
Read More
ENZA-p Trial: Enzalutamide With [177Lu]Lu-PSMA-617 Improves OS in mCRPC
Emily Menendez
RLT
|
March 7, 2025
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Read More
TALAPRO-2 and First-Line mCRPC Treatment: Insights on OS Benefits and Treatment Sequencing
Alan Tan, MD
CRPC
|
June 25, 2025
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
View More
Mevrometostat With Enzalutamide: Better Outcomes Compared With Enzalutamide Monotherapy for mCRPC
Emily Menendez
CRPC
|
February 25, 2025
The combination demonstrated a manageable safety profile with evidence of EZH2 pharmacodynamic inhibition and OR.
Read More
Final TALAPRO-2 Analysis: Talazoparib Plus Enzalutamide Significantly Improves Survival in HRR-Deficient mCRPC
Brandon Twyford
CRPC
|
February 21, 2025
Final TALAPRO-2 results show talazoparib + enzalutamide significantly improves survival in patients with HRR-deficient mCRPC.
Read More
Real-World Outcomes of Lu-PSMA-617 in mCRPC
Jordan Ciuro, MD
CRPC
|
February 14, 2025
New research sheds light on the real-world outcomes of Lu-PSMA-617 in a racially diverse patient population.
View More
TALAPRO-2: Final OS After First-Line Treatment for Patients With mCRPC
Zachary Bessette
CRPC
|
February 13, 2025
Tala/enza demonstrated improvement in OS compared with enza alone as 1L treatment in patients with mCRPC.
Read More
Load More
Advertisement
Advertisement